Equities

Panion & BF Biotech Inc

1760:TAI

Panion & BF Biotech Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (TWD)89.50
  • Today's Change0.20 / 0.22%
  • Shares traded68.52k
  • 1 Year change-19.73%
  • Beta--
Data delayed at least 20 minutes, as of Nov 22 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of TWD
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments535464349
Total Receivables, Net359361363
Total Inventory538546529
Prepaid expenses362331
Other current assets, total8.775.973.12
Total current assets1,4771,3991,275
Property, plant & equipment, net1,6351,5621,524
Goodwill, net4.214.213.79
Intangibles, net7.661216
Long term investments687584
Note receivable - long term------
Other long term assets202029
Total assets3,2353,0942,953
LIABILITIES
Accounts payable133125130
Accrued expenses------
Notes payable/short-term debt535395265
Current portion long-term debt/capital leases453070
Other current liabilities, total337372276
Total current liabilities1,051922740
Total long term debt14858168
Total debt728482503
Deferred income tax737374
Minority interest------
Other liabilities, total533438
Total liabilities1,3241,0861,020
SHAREHOLDERS EQUITY
Common stock857857857
Additional paid-in capital867871904
Retained earnings (accumulated deficit)211300209
Treasury stock - common------
Unrealized gain (loss)------
Other equity, total(24)(22)(37)
Total equity1,9112,0071,933
Total liabilities & shareholders' equity3,2353,0942,953
Total common shares outstanding868686
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.